![conference banner](/images/conference-banner.jpeg)
Abstract
Osteoarthritis (OA) is a slowly, progressive, ultimately degenerative disorder of movable joints, mainly characterized by joint pain and functional limitation and affecting all joint structures not just articular cartilage, but also the subchondral bone, ligaments, capsule, synovial membrane, and menisci. OA occurs when the equilibrium between breakdown and repair of the joint tissues becomes unbalanced. There are currently no pharmacological interventions available to patients for modifying the underlying disease (DMOADs) in relation to major drug development challenges. The current regulatory draft guidances for clinical development programs for DMOAD agents suggest radiographic joint space narrowing (JSN) as a primary endpoint. However, research efforts must continue to characterize imaging alternatives with greater sensitivity to change to enable development of new DMOADs. Past experience with DMOAD clinical trials indicate that pharmacologic agents must demonstrate pristine safety, and that consideration for special populations is important to avoid failed studies. More research is needed to determine what constitutes clinically meaningfulness for DMOAD activity in particular as it relates to OA progression. Current research pursues a variety of molecular targets including anti-catabolic agents to slow or halt OA progression and anabolic drugs to induce cartilage regrowth.
Keywords: Osteoarthritis, structural progression, DMOADs, molecular targets
Current Drug Targets
Title: Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets
Volume: 11 Issue: 5
Author(s): Marie-Pierre Hellio Le Graverand-Gastineau
Affiliation:
Keywords: Osteoarthritis, structural progression, DMOADs, molecular targets
Abstract: Osteoarthritis (OA) is a slowly, progressive, ultimately degenerative disorder of movable joints, mainly characterized by joint pain and functional limitation and affecting all joint structures not just articular cartilage, but also the subchondral bone, ligaments, capsule, synovial membrane, and menisci. OA occurs when the equilibrium between breakdown and repair of the joint tissues becomes unbalanced. There are currently no pharmacological interventions available to patients for modifying the underlying disease (DMOADs) in relation to major drug development challenges. The current regulatory draft guidances for clinical development programs for DMOAD agents suggest radiographic joint space narrowing (JSN) as a primary endpoint. However, research efforts must continue to characterize imaging alternatives with greater sensitivity to change to enable development of new DMOADs. Past experience with DMOAD clinical trials indicate that pharmacologic agents must demonstrate pristine safety, and that consideration for special populations is important to avoid failed studies. More research is needed to determine what constitutes clinically meaningfulness for DMOAD activity in particular as it relates to OA progression. Current research pursues a variety of molecular targets including anti-catabolic agents to slow or halt OA progression and anabolic drugs to induce cartilage regrowth.
Export Options
About this article
Cite this article as:
Hellio Le Graverand-Gastineau Marie-Pierre, Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets, Current Drug Targets 2010; 11 (5) . https://dx.doi.org/10.2174/138945010791011893
DOI https://dx.doi.org/10.2174/138945010791011893 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Gene-Wide Approach: New Frontiers in Cardiovascular Genetic Epidemiology
Current Hypertension Reviews Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach
Current Pharmaceutical Design Role of Inhibitory BCR Co-Receptors in Immunity
Infectious Disorders - Drug Targets Molecule of the Month
Current Topics in Medicinal Chemistry The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design Biomimetic Approaches for Targeted Nanomedicine: Current Status and Future Perspectives
Current Drug Therapy Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Effects of Vitamin D Levels on Cardiovascular Diseases: A Systematic Review
Current Nutrition & Food Science Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Current Drug Safety Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design